Belimumab and Voclosporin: Clinical Insights and Payer Evaluations in Lupus Nephritis

Author(s):

Ryan Haumschild, PharmD, MS, MBAJorge Larranaga, MD

Panelists discuss the differences in efficacy and safety profiles between belimumab and voclosporin for lupus nephritis (LN) and how payers are evaluating their value, including considerations of cost-effectiveness in LN management.

EP: 1.Understanding the Clinical Burden and Prevalence of Lupus Nephritis

EP: 2.Cost Drivers in Lupus Nephritis

EP: 3.Urgency to Treat in Lupus Nephritis: Goals of Therapy and Early Diagnosis Strategies

EP: 4.Guideline Updates in Lupus Nephritis: Impacts on Clinical Decision-Making

EP: 5.Tailoring Lupus Nephritis Treatment: Key Considerations and Specialist Approaches

Now Viewing

EP: 6.Belimumab and Voclosporin: Clinical Insights and Payer Evaluations in Lupus Nephritis

What is your perspective on the differences between the efficacy and safety profiles of belimumab and voclosporin in the treatment of lupus nephritis (LN)? (Dr. Larranaga and Dr. Wells)

How are payers evaluating the value of belimumab and voclosporin in the management of LN? (Dr. Wigginton)

What does cost-effectiveness look like in LN management?